The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe
Introduction: Prescribing guidance for disease-modifying treatment (DMT) in multiple sclerosis (MS) is centred on a clinical diagnosis of relapsing–remitting MS (RRMS). DMT prescription guidelines and monitoring vary across countries. Standardising the approach to diagnosis of disease course, for ex...
Main Authors: | Richard Nicholas, Jeff Rodgers, James Witts, Annalaura Lerede, Tim Friede, Jan Hillert, Lars Forsberg, Anna Glaser, Ali Manouchehrinia, Ryan Ramanujam, Tim Spelman, Pernilla Klyve, Jiri Drahota, Dana Horakova, Hanna Joensen, Luigi Pontieri, Melinda Magyari, David Ellenberger, Alexander Stahmann, Helmut Butzkueven, Anneke Van Der Walt, Vladimir Bezlyak, Carol Lines, Rod Middleton |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-09-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/17562864231198963 |
Similar Items
-
Pregnancy Outcomes in Men and Women Treated With Teriflunomide. A Population-Based Nationwide Danish Register Study
by: Johanna Balslev Andersen, et al.
Published: (2018-11-01) -
Association of Pre-Disease Body Mass Index With Multiple Sclerosis Prognosis
by: Ali Manouchehrinia, et al.
Published: (2018-05-01) -
Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study
by: Hillert J, et al.
Published: (2024-10-01) -
Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry
by: Lisa-Marie Ohle, et al.
Published: (2021-06-01) -
010 Real-world experience with ocrelizumab in the MSBase registry – Australian RRMS cohort
by: Mark Slee, et al.
Published: (2021-08-01)